[A24-45] Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V
Last updated 01.08.2024
Project no.:
A24-45
Commission:
Commission awarded on 24.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-45_en
| Project no. | Title | Status |
|---|---|---|
| A22-06 | Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |